Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Seven Corners Capital Management, LLC's investment thesis on Merrimack Pharmaceuticals ($MACK) — Q4 2023 | Buyside Digest

$MACKNASDAQMerrimack Pharmaceuticals

BULL

Seven Corners Capital Management, LLC—MACK

Fund Letter

Q4 2023

Published December 31, 2023

Price pending

—

—Pitched

Pending market quote

Market CapN/A

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Merrimack Pharmaceuticals represents an uncorrelated CVR event play with substantial tax-sheltered cash potential. FDA approval of...

— Scott Klarquist

BSD Research Exclusive

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

Other investors who've written on Merrimack Pharmaceuticals

No other institutional pitches found for this ticker yet.